TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01870336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined treatment of medial knee osteoarthritis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined treatment of medial knee osteoarthritis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined treatment of medial knee osteoarthritis
Study: NCT00444054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet (approximately 20 grams per day)
Description: Very low carbohydrate diet for a duration of four weeks.
Study: NCT02598388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
Study: NCT02354404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ
Description: cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ
Description: cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO
Description: 1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO
Description: 1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO
Description: 1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO
Description: 1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Study: NCT01284452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50 ml intravenous every 6 hours for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg intravenous every 6 hours for 7 days
Study: NCT04756115

Intervention type: PROCEDURE
Intervention: Vascular Surgery.
Description: Open Vascular, endovascular or hybrid procedures.
Study: NCT02644915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%%NaCl solution
Description: 100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg
Study: NCT04659369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB819
Description: for injection only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: for injection only
Study: NCT00329082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5: Placebo QW IV for 12 weeks
Study: NCT03443531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Huatan granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yifei Qinghua granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Huatan granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Yifei Qinghua granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
Study: NCT00369941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0518
Description: 400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: efavirenz
Description: 600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Truvada
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Truvada
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to MK-0518
Description: Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to efavirenz
Description: Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
Study: NCT03706482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOOST cells
Description: Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOOST cells
Description: Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
Study: NCT04000282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442085
Description: Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442085
Description: Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
Study: NCT01644383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: logotherapy
Description: Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
Study: NCT01959061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 4mg, every 4 weeks,transhepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100\~150mg, every 4 weeks, transhepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: 5-20ml, every 4 weeks, hepatic artery embolization
Study: NCT00061932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT01640262

Intervention type: OTHER
Intervention: Multiparametric magnetic resonance imaging (mMRI)
Description: A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
Study: NCT03776461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study: NCT02295605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water-based exercises
Description: water-based exercise strengthening protocol for lower limb muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land-based exercises
Description: land-based exercise strengthening protocol for lower limb muscles
Study: NCT01805037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00288327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle behavior change program
Description: Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlets
Description: Nutritional and physical activity pamphlets from American Heart Association
Study: NCT03517566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily from baseline until week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 3mg
Description: ZPL389 3 mg oral powder; once daily from baseline to week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 10mg
Description: ZPL389 10 mg oral powder; once daily from baseline to week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 30mg
Description: ZPL389 30 mg oral powder; once daily from baseline to week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 50mg
Description: ZPL389 50 mg oral powder; once daily from baseline to week 16
Study: NCT03883932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatherhood Focused FVEP (F3)
Description: F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Violence Education Program (FVEP)
Description: FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
Study: NCT02488681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Pacemaker Implant
Study: NCT02973308

Intervention type: OTHER
Group type: OTHER
Intervention: Observer
Description: Observer A and observer B

Intervention type: OTHER
Group type: OTHER
Intervention: Observer
Description: Observer A and observer B

Intervention type: OTHER
Group type: OTHER
Intervention: Observer
Description: Observer A and observer B
Study: NCT00003824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg oral bid for 3 days starting the night before resection
Study: NCT00697242

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
Description: Intramuscular injection, 3 doses
Study: NCT02978339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
Study: NCT01721213

Intervention type: DRUG
Intervention: Trobalt™
Description: Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.

Intervention type: DRUG
Intervention: Trobalt™
Description: Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.

Intervention type: DRUG
Intervention: Trobalt™
Description: Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
Study: NCT03045497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo contrast-enhanced ultrasound imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced Magnetic Resonance Imaging
Study: NCT04414150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1802
Description: This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
Study: NCT02973308

Intervention type: OTHER
Group type: OTHER
Intervention: Observer
Description: Observer A and observer B
Study: NCT01087216

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group Laser = Arm A
Description: Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bras B : The group control
Description: patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
Study: NCT00844558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: There is no intervention associated with this arm of the study
Study: NCT02307162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: Phosphodiesterase 3 and 4 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dummy solution
Study: NCT04505579

Intervention type: DEVICE
Intervention: Anterior Vertebral Body Tethering
Description: Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
Study: NCT04038762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cuff deflation-inflation -deflation method
Description: Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cuff deflation-inflation -deflation method
Description: Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
Study: NCT00871962

Intervention type: OTHER
Intervention: OXYGEN SUPPLEMENTATION
Description: Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
Study: NCT00028574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03576573

Intervention type: DEVICE
Intervention: PROCOTYL® C
Description: Hip Arthroplasty
Study: NCT05551507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018 in combination with PLD
Description: IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
Study: NCT02555384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crowded drawing task
Description: Marking inverted signs on a sheet where symbols are presented close to one another

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: uncrowded drawing task
Description: Marking inverted signs on a sheet where there is a larger distance between symbols
Study: NCT04607369

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing

Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing
Study: NCT03777319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone will be prescribed for 6 months as the clinical standard of care.
Study: NCT01356199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARTRONAT
Description: Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO. 6 per day for 8 months.